In 1986, a population study of school children in the city of Coventry gave an overall prevalence in males and females for fragile X syndrome of 11952. The 29 children diagnosed as having fragile X syndrome in this study have been re-evaluated with molecular diagnostic techniques. Eighteen of the original 29 children have been found not to have the expansion of the FMR1 gene associated with fragile X syndrome. Revised prevalence figures have been calculated giving rise to an overall prevalence figure of 1/2720 (range 112198-1/3089). If the four children lost to follow up are also assumed not to have the fragile X syndrome, the revised prevalence figure was 1/5714 (range 1/4762-116349). Clinical review of boys with severe mental retardation from this and a subsidiary study show that the clinical features of head circumference greater than the 50th centile, testicular volume greater than the 50th centile, and IQ between 35 and 70 remain helpful in distinguishing boys with fragile X syndrome from those who have nonspecific mental retardation.
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In 1986, a population study was performed among school children in the city of Coventry in order to ascertain the frequency of mental retardation associated with the fragile X chromosome.' The prevalence of fragile X syndrome in the 11 to 16 year old age group (the age of the greatest ascertainment) was found to be 1 in 952 and the fragile X syndrome has therefore been considered to be a major cause of mental retardation.
In 1990, Sutherland and Baker2 described the non-pathological fragile site at Xq27.2 (FRAXD). Webb and Bundey' therefore reanalysed their data from the Coventry study, excluding those children thought to have FRAXD. The numbers of affected boys fell from 16 to 14 and of affected girls from 13 to 11. These changes made little difference to the prevalence figure which was re-estimated as 1 in 1039. Moreover, the number of educationally subnormal (ESN) children at schools for mild retardation (ESN(M)) with fragile X syndrome still exceeded those at schools for severe mental retardation (ESN(S)) in both boys and girls (17 ESN(M) and eight ESN(S)). Fragile X syndrome was therefore still considered to be an important cause of mental retardation, especially in children with mild to moderate mental retardation. It was pointed out in this revised article that the number of children diagnosed with fragile X syndrome in the West Midlands as a whole in the years between 1980 and 1984 was considerably less than would be expected according to the estimated prevalence.
In 1991, the fragile X gene (FMR1)"6 was cloned, and we therefore analysed once more the data from the original study of Coventry school children. Since previous investigations have suggested that most children with the fragile X syndrome have mild to moderate mental retardation, we also re-evaluated the level of learning difficulties in the children still thought to have the condition.
Previous studies have tried to elucidate clinical pointers helpful in suggesting the diagnosis of fragile X syndrome in a child with otherwise unexplained mental retardation.79 In 1985, Thake et all' addressed this in a population study of 156 boys with severe mental retardation. This series included the boys from the ESN(S) schools from the 1986 Coventry study and additional boys from five other education authorities. A total of 14 out of the 156 boys were diagnosed as having fragile X syndrome with cytogenetic testing. The clinical features which helped to distinguish the 14 boys with fragile X syndrome from those without were evaluated. This population ofboys has also been evaluated using molecular diagnostic techniques and the usefulness of these clinical indicators reassessed.
Methods
Attempts were made to recontact all of the children from the two previous studies"'°and permission was sought for a repeat blood sample to be taken from each subject previously diagnosed as being affected by fragile X syndrome.
Where permission was obtained, blood was taken for repeat cytogenetic and molecular analysis. Cytogenetic studies were performed using standard techniques with excess thymidine. Figure 1 Diagram to show the number of children at ESN(S) and ESN(M) schools in the "Coventry study" who are still thought to have fragile X syndrome.
Molecular analysis was performed using Southern blots of genomic DNA digested with EcoRI and EagI and hybridisation with the DNA Table 5 shows the IQ levels for both boys and girls thought to have fragile X syndrome after the original study in 1986, and following the exclusion of children with FRAXD or no molecular evidence of FRAXA. As expected, the girls tended to have higher IQs than the boys. No children, girls or boys, remain in the most severe group with an IQ of less than 20 and only two children (both boys) remain who had an IQ of less than 35.
None of the children who were found not to have FRAXA was subsequently found to have FRAXE or FRAXF to explain the fragile site which had been observed cytogenetically. The most recent cytogenetic results of these non-FRAXA, E, or F cases showed a low level of expression in more than half (expression < 5% in 11/18 and 6-10% in 7/18). Discussion There have been a number of studies using cytogenetic data to estimate the prevalence of fragile X syndrome""'' (table 6) , and a prevalence ofaround 1/1000 was widely quoted and accepted before molecular studies were possible. It has, however, been suspected for some time that this figure is too high,'8123 or if it is not too high, then the condition is being under diagnosed.2324 Jacobs et al,2' in their molecular study of children with mental impairment, estimated the population frequency of fragile X syndrome to be 1 in approximately 9000 and a minimum population prevalence of 1 in 4130 was estimated by Slaney et al.23 Since the study by Webb et al' is thought to have achieved complete ascertainment, this provided a very good opportunity to try and establish more accurate prevalence figures for a total population of school children. It came as no great surprise that fragile X syndrome is less common than originally thought, although it is perhaps surprising quite how many children have been excluded from the original study. There are several possible reasons for the false positive diagnoses in the original "Coventry study". As has already been mentioned, four of the Coventry school children were excluded once the common, non-pathological fragile site was recognised. Of the children excluded after molecular investigation, many only had low expression of a fragile site on cytogenetic testing. In the original study children were classified as "positive" for the fragile X if the abnormal chromosome was present in 3% or rniore of their cells. The current criteria used by our cytogenetics laboratory is .5% for a positive result. Hence, although the diagnosis of fragile X syndrome was legitimate at the time, the diagnosis in many of the children would not have been made using current diagnostic criteria.
Of the seven non-FRAXA, non-FRAXD children, who had cytogenetic expression between 6 and 10% when originally studied, four were not found to express a fragile site on retesting in 1994. The reason for this is not clear, but may be related to the different culture conditions now used. In the 1986 study, culture media without available folic acid were achieved by a combination of direct deficiency and the use of folate antagonists together with excess thymidine, whereas current practice is to use excess thymidine alone.
Another explanation is that the non-FRAXA, non-FRAXD patients have FRAXE or FRAXF. Testing for expansions at these sites did not, however, find this to be the case. In 1985, Thake et all' compiled a table summarising the usefulness of various clinical features as indicators of fragile X syndrome in boys at ESN(S) schools. The combination of apparently most useful features was IQ in the 35-70 range, head circumference greater than the 50th centile, and testicular volume in boys aged 10 or over above the 50th centile. This combination of features gave a 1 in 3.6 chance of picking a child with fragile X syndrome (compared with 1 in 9 for the group as a whole). Conversely, 1 in 5 boys in the fragile X syndrome group would have been missed using this combination of features. Re-evaluation of these figures after cytogenetic and molecular review showed that although this combination of features still helped as a clinical pointer for picking out children with fragile X syndrome from a group of children with idiopathic mental retardation at ESN(S) schools, a significant number would be missed (1 in 4) using these criteria. Since there are no clear cut clinical criteria to differentiate boys with fragile X syndrome from those who have non-specific mental retardation, testing for the fragile X syndrome is still recommended, but the above clinical features increase the chance of a positive result while at the same time excluding a number of boys with non-specific mental retardation.
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